Abstract
The plant kingdom is a rich source of compounds with anticancer activities. Curcumin [1,7-bis(4-hydroxy-3- methoxyphenyl)-1,6-heptadiene-3,5-dione] (1) is a secondary metabolite produced by rhizomes of Curcuma longa that has been used for centuries in traditional Medicine in Asia. Anticancer activity is one of the pharmacological properties of curcumin (1) that has been widely explored. Its targets include transcription factors, growth and angiogenesis regulators, apoptosis-related genes, adhesion-related molecules, and cellular signaling molecules. Some curcumin conjugates and metallocomplexes have been synthesized, characterized and evaluated for anticancer activity. In this mini-review, we discuss the mechanism of action by which curcumin (1) inhibits the progression of tumor growth and also the antiproliferative activity of curcumin conjugates and metallocomplexes on human cancer cells. The understanding of how these conjugates and metallocomplexes exert their anticancer activities is essential for future development of effective drugs.
Keywords: Curcumin, Curcumin conjugates and metallocomplexes, Cancer, Antiproliferative activity
Current Bioactive Compounds
Title: Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Volume: 4 Issue: 3
Author(s): Angelo de Fatima, Luzia V. Modolo, Ana Tereza M. Neres, Carmen V. Ferreira and Ana Carolina S. de Souza
Affiliation:
Keywords: Curcumin, Curcumin conjugates and metallocomplexes, Cancer, Antiproliferative activity
Abstract: The plant kingdom is a rich source of compounds with anticancer activities. Curcumin [1,7-bis(4-hydroxy-3- methoxyphenyl)-1,6-heptadiene-3,5-dione] (1) is a secondary metabolite produced by rhizomes of Curcuma longa that has been used for centuries in traditional Medicine in Asia. Anticancer activity is one of the pharmacological properties of curcumin (1) that has been widely explored. Its targets include transcription factors, growth and angiogenesis regulators, apoptosis-related genes, adhesion-related molecules, and cellular signaling molecules. Some curcumin conjugates and metallocomplexes have been synthesized, characterized and evaluated for anticancer activity. In this mini-review, we discuss the mechanism of action by which curcumin (1) inhibits the progression of tumor growth and also the antiproliferative activity of curcumin conjugates and metallocomplexes on human cancer cells. The understanding of how these conjugates and metallocomplexes exert their anticancer activities is essential for future development of effective drugs.
Export Options
About this article
Cite this article as:
de Fatima Angelo, Modolo V. Luzia, Neres M. Ana Tereza, Ferreira V. Carmen and de Souza S. Ana Carolina, Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review, Current Bioactive Compounds 2008; 4 (3) . https://dx.doi.org/10.2174/157340708786305934
DOI https://dx.doi.org/10.2174/157340708786305934 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer
Current Drug Targets The CLCA Gene Family: Putative Therapeutic Target for Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Regulation of Expression and Function of IDO in Human Dendritic Cells
Current Medicinal Chemistry Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions
Current Medicinal Chemistry Phenothiazine: The Parent Molecule
Current Drug Targets 177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma
Current Radiopharmaceuticals Phytocompounds from the Medicinal and Dietary Plants: Multi-target Agents for Cervical Cancer Prevention and Therapy
Current Medicinal Chemistry Involvement of Nucleotide Excision and Mismatch Repair Mechanisms in Double Strand Break Repair
Current Genomics Furan-induced Oxidative Stress and DNA Damage in Diabetic and Nondiabetic Rats’ Blood and Protective Effect of Lycopene
Current Nutrition & Food Science In Vitro High Throughput Phage Display Selection of Ovarian Cancer Avid Phage Clones for Near-Infrared Optical Imaging
Combinatorial Chemistry & High Throughput Screening Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets Electrochemical Biosensors as a Screening Tool of In Vitro DNA-Drug Interaction
Current Pharmaceutical Analysis A Structural Insight into Hydroxamic Acid Based Histone Deacetylase Inhibitors for the Presence of Anticancer Activity
Current Medicinal Chemistry Study of drug-drug combinations based on molecular descriptors and physicochemical properties
Combinatorial Chemistry & High Throughput Screening Carcinogenicity and Chronic Rodent Toxicity of the Selective Progesterone Receptor Modulator Ulipristal Acetate
Current Drug Safety Probiotics: From Functional Foods to Pharmaceutical Products
Current Pharmaceutical Biotechnology Lymphatics and Inflammation
Current Medicinal Chemistry Molecular and Cellular Mechanisms of Hexavalent Chromium-Induced Lung Cancer: An Updated Perspective
Current Drug Metabolism